Skip to content

Comparison between misoprostol and oxytocine in cervical ripening for labour induction: a randomized clinical trial

Comparison between misoprostol and oxytocine in cervical ripening for labour induction: a randomized clinical trial

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT2012103011324N1
Enrollment
190
Registered
2013-01-13
Start date
2013-01-20
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Failed medical induction of labour. Failed induction (of labour) by:•oxytocin•prostaglandins

Interventions

Intervention 1: For women who receive misopristol, 50 mcg of medication in posterior fornix of vagina will be placed. The dose every 4 hours to 25 mcg can be repeated up to a pattern of at least 3 con
Treatment - Drugs
For women who receive misopristol, 50 mcg of medication in posterior fornix of vagina will be placed. The dose every 4 hours to 25 mcg can be repeated up to a pattern of at least 3 contraction in 10 m
For oxytocin group 2 mU/min of the drug for intravenous infusion will be used in intervals of 30 minutes 2 times the amount of the drug, as long as proper contractile pattern. The dose up to maximum

Sponsors

Ahwaz Jundishapur University of Medical Science, Vice Chancellor for Research and Technology
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: Entry criteria : Medical indication for the induction of delivery; Single twin pregnancies; Gestational age more than 36 weeks; Vertex presentation ;The normal heart rate of embryos .The exit criteria: The embryo-pelvic dystocia; An estimated weight of over 4000 grams or evidence of a lack of fitness cephalopelvic ; Abnormal vaginal bleeding or any placenta previa; The number of pregnancy over 4; Fetal malformation; Previous uterine scar; Any situation that does not cause vaginal delivery indication, Any contraindication use of misopristol ; Severe polyhydramnios

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Bishop index. Timepoint: Baseline and every 30 minutes during the intervention and at the end of the intervention. Method of measurement: The questionnaire.

Secondary

MeasureTime frame
Infantile complication. Timepoint: Baseline and every 30 minutes during the intervention and at the end of the intervention. Method of measurement: Apgar score.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMehrnooh Namazi

Ahwaz Jndishapur University of Medical Sciences

mohamadjafari-r@ajums.ac.ir ; alinazeri_76@yahoo.com ; mnamazi1979@yahoo.com+91 63006324

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026